ATOS
Price
$0.69
Change
+$0.04 (+6.15%)
Updated
Apr 2, 02:34 PM (EDT)
Capitalization
87.11M
47 days until earnings call
PDSB
Price
$1.15
Change
+$0.07 (+6.48%)
Updated
Apr 2, 04:59 PM (EDT)
Capitalization
52.62M
42 days until earnings call
Ad is loading...

ATOS vs PDSB

Header iconATOS vs PDSB Comparison
Open Charts ATOS vs PDSBBanner chart's image
Atossa Therapeutics
Price$0.69
Change+$0.04 (+6.15%)
Volume$250
Capitalization87.11M
PDS Biotechnology
Price$1.15
Change+$0.07 (+6.48%)
Volume$6.22K
Capitalization52.62M
ATOS vs PDSB Comparison Chart
Loading...
ATOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PDSB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATOS vs. PDSB commentary
Apr 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATOS is a Buy and PDSB is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 02, 2025
Stock price -- (ATOS: $0.65 vs. PDSB: $1.08)
Brand notoriety: ATOS and PDSB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATOS: 85% vs. PDSB: 64%
Market capitalization -- ATOS: $87.11M vs. PDSB: $52.62M
ATOS [@Biotechnology] is valued at $87.11M. PDSB’s [@Biotechnology] market capitalization is $52.62M. The market cap for tickers in the [@Biotechnology] industry ranges from $302.51B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATOS’s FA Score shows that 1 FA rating(s) are green whilePDSB’s FA Score has 0 green FA rating(s).

  • ATOS’s FA Score: 1 green, 4 red.
  • PDSB’s FA Score: 0 green, 5 red.
According to our system of comparison, both ATOS and PDSB are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATOS’s TA Score shows that 4 TA indicator(s) are bullish while PDSB’s TA Score has 4 bullish TA indicator(s).

  • ATOS’s TA Score: 4 bullish, 4 bearish.
  • PDSB’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, PDSB is a better buy in the short-term than ATOS.

Price Growth

ATOS (@Biotechnology) experienced а -10.06% price change this week, while PDSB (@Biotechnology) price change was -18.18% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.95%. For the same industry, the average monthly price growth was -7.12%, and the average quarterly price growth was -11.69%.

Reported Earning Dates

ATOS is expected to report earnings on May 19, 2025.

PDSB is expected to report earnings on May 14, 2025.

Industries' Descriptions

@Biotechnology (-4.95% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ATOS($87.1M) has a higher market cap than PDSB($52.6M). ATOS YTD gains are higher at: -31.045 vs. PDSB (-33.742). ATOS has higher annual earnings (EBITDA): -29.46M vs. PDSB (-36.65M). ATOS has more cash in the bank: 74.8M vs. PDSB (49.8M). ATOS has less debt than PDSB: ATOS (0) vs PDSB (24.7M). ATOS (0) and PDSB (0) have equivalent revenues.
ATOSPDSBATOS / PDSB
Capitalization87.1M52.6M166%
EBITDA-29.46M-36.65M80%
Gain YTD-31.045-33.74292%
P/E RatioN/AN/A-
Revenue00-
Total Cash74.8M49.8M150%
Total Debt024.7M-
FUNDAMENTALS RATINGS
ATOS vs PDSB: Fundamental Ratings
ATOS
PDSB
OUTLOOK RATING
1..100
552
VALUATION
overvalued / fair valued / undervalued
1..100
28
Undervalued
41
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9699
PRICE GROWTH RATING
1..100
9092
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATOS's Valuation (28) in the Medical Specialties industry is in the same range as PDSB (41) in the Pharmaceuticals Major industry. This means that ATOS’s stock grew similarly to PDSB’s over the last 12 months.

ATOS's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as PDSB (100) in the Pharmaceuticals Major industry. This means that ATOS’s stock grew similarly to PDSB’s over the last 12 months.

ATOS's SMR Rating (96) in the Medical Specialties industry is in the same range as PDSB (99) in the Pharmaceuticals Major industry. This means that ATOS’s stock grew similarly to PDSB’s over the last 12 months.

ATOS's Price Growth Rating (90) in the Medical Specialties industry is in the same range as PDSB (92) in the Pharmaceuticals Major industry. This means that ATOS’s stock grew similarly to PDSB’s over the last 12 months.

ATOS's P/E Growth Rating (100) in the Medical Specialties industry is in the same range as PDSB (100) in the Pharmaceuticals Major industry. This means that ATOS’s stock grew similarly to PDSB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATOSPDSB
RSI
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 17 days ago
81%
Bullish Trend 6 days ago
87%
Declines
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
View a ticker or compare two or three
Ad is loading...
ATOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PDSB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
KKOYY10.260.09
+0.91%
Kesko OY
PRNDY19.940.14
+0.71%
Pernod Ricard S.A.
GPOX0.04N/A
N/A
GPO PLUS INC.
KYOCY11.27-0.05
-0.44%
Kyocera Corp.
LICYF0.33-0.03
-8.64%
Li-Cycle Holdings Corp.

ATOS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATOS has been loosely correlated with ABOS. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ATOS jumps, then ABOS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATOS
1D Price
Change %
ATOS100%
-3.25%
ABOS - ATOS
48%
Loosely correlated
-2.27%
ABCL - ATOS
43%
Loosely correlated
-6.28%
AXON - ATOS
42%
Loosely correlated
+2.90%
GBIO - ATOS
41%
Loosely correlated
-9.11%
NTLA - ATOS
41%
Loosely correlated
-6.40%
More

PDSB and

Correlation & Price change

A.I.dvisor indicates that over the last year, PDSB has been loosely correlated with AXON. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if PDSB jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PDSB
1D Price
Change %
PDSB100%
-9.24%
AXON - PDSB
43%
Loosely correlated
+2.90%
RXRX - PDSB
43%
Loosely correlated
-3.69%
KYMR - PDSB
41%
Loosely correlated
-7.80%
ATOS - PDSB
37%
Loosely correlated
-3.25%
ATXS - PDSB
36%
Loosely correlated
+1.12%
More